Amexdrug Corporation
Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of p… Read more
Amexdrug Corporation (AXRX) - Net Assets
Latest net assets as of June 2025: $1.81 Million USD
Based on the latest financial reports, Amexdrug Corporation (AXRX) has net assets worth $1.81 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.42 Million) and total liabilities ($609.68K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.81 Million |
| % of Total Assets | 74.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | 39.44% |
| 10-Year Change | 235.74% |
| Growth Volatility | 75.46 |
Amexdrug Corporation - Net Assets Trend (2001–2024)
This chart illustrates how Amexdrug Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amexdrug Corporation (2001–2024)
The table below shows the annual net assets of Amexdrug Corporation from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.76 Million | +0.65% |
| 2023-12-31 | $1.75 Million | +6.40% |
| 2021-12-31 | $1.65 Million | +8.69% |
| 2020-12-31 | $1.52 Million | +19.80% |
| 2019-12-31 | $1.27 Million | +23.05% |
| 2018-12-31 | $1.03 Million | +27.48% |
| 2017-12-31 | $806.69K | +15.64% |
| 2016-12-31 | $697.60K | +11.66% |
| 2015-12-31 | $624.77K | +18.88% |
| 2014-12-31 | $525.55K | +22.32% |
| 2012-12-31 | $429.65K | +23.26% |
| 2011-12-31 | $348.58K | +39.15% |
| 2010-12-31 | $250.51K | +293.87% |
| 2009-12-31 | $63.60K | +17.78% |
| 2008-12-31 | $54.00K | +28.57% |
| 2007-12-31 | $42.00K | +40.00% |
| 2006-12-31 | $30.00K | +200.00% |
| 2005-12-31 | $10.00K | +112.50% |
| 2004-12-31 | $-80.00K | +12.09% |
| 2003-12-31 | $-91.00K | +21.55% |
| 2002-12-31 | $-116.00K | -18.37% |
| 2001-12-31 | $-98.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amexdrug Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 158364200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.58 Million | 89.75% |
| Common Stock | $169.41K | 9.60% |
| Other Comprehensive Income | $11.44K | 0.65% |
| Total Equity | $1.76 Million | 100.00% |
Amexdrug Corporation Competitors by Market Cap
The table below lists competitors of Amexdrug Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Marine Food Gr
PINK:CMFO
|
$19.23 |
|
STRATEX INTL
BE:S1Y
|
$19.39 |
|
PROPLASTICS LIMITED
XZIM:PROL
|
$19.50 |
|
ICFG Limited
LSE:ICFG
|
$19.53 |
|
INTERNATIONAL ENERGY INSURANCE PLC
XNSA:INTENEGINS
|
$19.14 |
|
MFM Korea Co. Ltd.
KO:323230
|
$19.10 |
|
Solartron PCL
STU:TUU
|
$19.07 |
|
Inspirit Energy Holdings Plc
LSE:INSP
|
$19.06 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amexdrug Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,753,052 to 1,764,488, a change of 11,436 (0.7%).
- Net income of 11,436 contributed positively to equity growth.
- Other comprehensive income decreased equity by 24,397.
- Other factors increased equity by 24,397.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $11.44K | +0.65% |
| Other Comprehensive Income | $-24.40K | -1.38% |
| Other Changes | $24.40K | +1.38% |
| Total Change | $- | 0.65% |
Book Value vs Market Value Analysis
This analysis compares Amexdrug Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.19x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $0.00 | $0.00 | x |
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2015-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.01 | $0.00 | x |
| 2019-12-31 | $0.01 | $0.00 | x |
| 2020-12-31 | $0.01 | $0.00 | x |
| 2021-12-31 | $0.01 | $0.00 | x |
| 2023-12-31 | $0.01 | $0.00 | x |
| 2024-12-31 | $0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amexdrug Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.34%
- • Asset Turnover: 1.37x
- • Equity Multiplier: 1.41x
- Recent ROE (0.65%) is below the historical average (29.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 140.00% | 0.28% | 10.72x | 46.20x | $13.00K |
| 2006 | 70.00% | 0.45% | 9.41x | 16.47x | $18.00K |
| 2007 | 26.19% | 0.18% | 8.83x | 16.55x | $6.80K |
| 2008 | 22.22% | 0.21% | 8.03x | 13.13x | $6.60K |
| 2009 | 28.85% | 0.19% | 12.23x | 12.55x | $11.99K |
| 2010 | 75.47% | 1.65% | 8.56x | 5.36x | $164.01K |
| 2011 | 28.87% | 0.81% | 7.76x | 4.59x | $65.79K |
| 2012 | 19.09% | 0.90% | 3.80x | 5.60x | $39.07K |
| 2014 | 14.55% | 0.89% | 6.20x | 2.65x | $23.90K |
| 2015 | 16.06% | 1.13% | 4.91x | 2.89x | $37.84K |
| 2016 | 10.57% | 0.79% | 4.00x | 3.34x | $4.00K |
| 2017 | 13.81% | 1.07% | 4.51x | 2.87x | $30.69K |
| 2018 | 19.58% | 1.92% | 3.85x | 2.66x | $98.56K |
| 2019 | 17.14% | 2.81% | 3.12x | 1.95x | $90.35K |
| 2020 | 12.93% | 3.08% | 1.72x | 2.44x | $44.39K |
| 2021 | 4.50% | 1.54% | 1.68x | 1.75x | $-90.57K |
| 2023 | 2.04% | 0.92% | 1.59x | 1.40x | $-139.47K |
| 2024 | 0.65% | 0.34% | 1.37x | 1.41x | $-165.01K |
Industry Comparison
This section compares Amexdrug Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amexdrug Corporation (AXRX) | $1.81 Million | 140.00% | 0.34x | $19.17 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |